Painchek Ltd · ASX:PCK
Painchek — Corporate Update (July 2023)
32 slides from Painchek's corporate update, Jul 27, 2023
Slide 1: ASX Announcement: Investor Presentation Webinar
ASX ANNOUNCEMENT 27 July 2023 INVESTOR PRESENTATION WEBINAR 11am THURSDAY 27TH JULY 2023 Further to the webinar announcement on 25 July 2023, PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, is pleas
Slide 2: About PainChek
pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates. PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively ver
Slide 3: Quarterly Update July 2023
For personal use only Quarterly Update July 2023 PHILIP DAFFAS, CEO & MD PAINCHEK LTD | ASX:PCK 1 |
Slide 4: Our purpose is to give a voice to people who cannot verbalise pain
For personal use only Our purpose is to give a voice to people who cannot reliably verbalise their pain
Slide 5: Introduction to PainChek
INTRODUCTION TO PAINCHEK For personal use only PainChek’s SAAS platform delivers Multiple large new global Regulatory clearance in unique evidence based pain market opportunities in multiple markets, supported detection technology using AI hospitals and home care by peer reviewed clinical and smart
Slide 6: The Breadth of PainChek's Global Market Opportunity
THE BREADTH OF PAINCHEK’s GLOBAL MARKET OPPORTUNITY For personal use only 400M pre-verbal children1 25-42% of hospital beds occupied by people with dementia4,5 57M people living with dementia >150M expected by 20502,3 1. Ecology Communications Group. www.ecology.com/birth-death-rates 4. Tsai, I. P.,
Slide 7: PainChek Well Positioned to Exploit Large Global Market Opportunities
PAINCHEK WELL POSITIONED TO EXPLOIT LARGE GLOBAL MARKET OPPORTUNITES For personal use only AGED CARE MARKET HOME CARE INFANT MARKET HOSPITAL MARKET 6 MILLION BEDS UP TO 10X AGED 400M PRE-VERBAL ~$1Bn ANNUALLY & CARE MARKET CHILDREN - 150M ANNUALLY to $300M ANNUAL FIRST TIME PARENTS ARR 5
Slide 8: PainChek Around the World and Across Australia
PAINCHEK AROUND THE WORLD…AND ACROSS AUSTRALIA 1000+ Aged Care facilities across 3 continents Canada For personal use only • Initial RAC sales now in place and implemented • Exploring additional Europe (EU) Aged Care and Home Japan Care partners for North • Targeting RAC beds America and home care •
Slide 9: June Quarter Highlights Confirm Rapid Scalability in Multiple Markets
PAINCHEK JUNE QUARTER HIGHLIGHTS CONFIRM PCK’s RAPID SCALABILITY IN MULTIPLE MARKETS For personal use only 96% 89% 99% 90% 150% 85% increase increase in increase in increase in annual Strong UK annual client retention in global contracted ARR annual customer customer receipts growth with a 25% rate
Slide 10: Strong Growth and Pipeline in ANZ & UK Aged Care
STRONG GROWTH AND PIPELINE IN ANZ & UK AGED CARE For personal use only Global - Contracted Licences 80,000 96% increase in annual contracted bed licences 70,007 over prior year 70,000 +96% p.a. 64,163 60,000 150% increase in UK contracted beds to 18,800 55,254 beds over prior year in a 440,000 bed m
Slide 11: Strong ARR Growth at High Gross Margins
STRONG ARR GROWTH AT HIGH GROSS MARGINS For personal use only Global - ARR $m 4.00 89% increase in ARR1 over the prior year $3.4 3.50 +89% p.a. $3.1 SAAS business model with 70-85% gross 3.00 $2.4 % margins2 on annual licences 2.50 2.00 $1.8 $1.9 85% retention rate of on annual renewals 1.50 Rapid U
Slide 12: Strong Growth in Recognised Revenue
STRONG GROWTH IN RECOGNISED REVENUE For personal use only Quarterly Customer Revenue- (A$) (June 2023 Unaudited) $1,951,300 $700,000 $2,000,000 99% annual increase in 12 month trailing $1,689,809 $1,800,000 revenue $600,000 $1,600,000 $1,419,345 $500,000 $1,400,000 6% increase in Q4 FY23 revenue on
Slide 13: Consistent Growth in Utility
CONSISTENT GROWTH IN UTILITY Cumulative Number of UNAUDITED JUNE 2023 DATA – For personal use only PainChek® Assessments QUARANTINED FOR RELEASE 3,500,000 Over 2.9 million global pain assessments 3,000,000 conducted on the PainChek platform 2,500,000 115% increase over the previous year in Aged Care
Slide 14: PainChek Across Australia
PAINCHEK ACROSS AUSTRALIA AGED CARE’s MOST POPULAR DIGITAL CLINICAL TOOL Aged Care For personal use only PainChek® has been widely adopted across Aged Care in Australia. PainChek commercial licences cover more than 50,000 beds and 700 aged care homes, approximately 25% of total AU market and growing
Slide 15: UK – 150% Annual Growth into the 440,000 Bed Market
UK – 150% ANNUAL GROWTH INTO THE 440,000 BED RESIDENTIAL AGED CARE MARKET For personal use only UK market traction accelerated – London Borough of Enfield Local New RAC clients in Qtr ~19,000 contracted beds (150% Authority has contracted with include Exemplar growth in year) with ~8,000 live PainCh
Slide 16: Outstanding Outcomes from Regular Pain Monitoring
OUTSTANDING OUTCOMES FROM REGULAR PAIN MONITORING IS DRIVING RAPID NEW CLIENT GROWTH IN THE UK For personal use only Regular pain monitoring has delivered outstanding results Ability to identify and treat Reduce levels of stress and distress Reduced stress and distress from unreported fractures1 fro
Slide 17: The PainChek Solution
For personal use only THE PAINCHEK® SOLUTION ADDRESSING A GLOBAL MARKET NEED
Slide 18: Pain Management Challenges
PAIN MANAGEMENT CHALLENGES For personal use only • Difficulties in assessing Pain Up to • Complex 80% of people in aged • Dynamic care experience • Multidimensional chronic pain1 • Subjective • Education & Training More than • Reporting & Documentation 70% of people in aged care have • Continuous Mo
Slide 19: The Evolution of Pain Assessment
THE EVOLUTION OF PAIN ASSESSMENT Legacy Pain For personal use only PainChek® Assessment Tools “The PainChek app, which I see as a welcome evolutionary development of my past work, was introduced to improve pain management practices by ensuring an evidence-based assessment of pain could be made at th
Slide 20: The PainChek Universal App: Quick and Easy Operation
THE PAINCHEK® UNIVERSAL APP: QUICK AND EASY OPERATION AI based micro-facial pain expression analysis: For personal use only A medical • 3 second scan of patient face device in • recognises 9 micro-facial expressions indicative of pain your pocket Guided Digital questionnaire checklist: • guides the
Slide 21: PainChek Analytics
PAINCHEK ANALYTICS PainChek® Analytics provides actionable insights from the PainChek® pain assessment data which helps reduce clinical risk, ensure pain is identified early and enable clients to focus on providing care. For personal use only Detailed analytics and reports developed with insights fr
Slide 22: PainChek Global Market Strategy and Partnerships
For personal use only PAINCHEK® GLOBAL MARKET STRATEGY AND PARTNERSHIPS
Slide 23: PainChek Global Market Strategy
PAINCHEK GLOBAL MARKET STRATEGY For personal use only BUSINESS MODEL TARGET MARKETS/USERS B2B Enterprise: licence • Dementia &/geriatric wards • Hospitals • ER/Post surgical care • Care Homes • Residential & home care providers • Home care Healthcare • Primary Care PainChek Professionals Adult BUSIN
Slide 24: PainChek's Partners: Access to 1,500,000 Aged Care Beds
PAINCHEK’S PARTNERS: ACCESS TO 1,500,000 AGED CARE BEDS AND A PATHWAY TO ACCELERATED GLOBAL GROWTH PainChek integrates and works with aged care management and medication management systems covering more than 1,500,000 For personal use only aged care beds across ANZ, UK and North America These integr
Slide 25: Market Partnerships and Drivers for USA & Canada
MARKET PARTNERSHIPS AND DRIVERS FOR USA & CANADA For personal use only PAINCHEK IS TARGETING FDA DE NOVO CLEARANCE AND US LAUNCH IN 2024 PointClickCare: PainChek integrated with NORTH AMERICAN LONG TERM CARE PointClickCare leading long term care MARKET OPPORTUNITY provider in USA & Canada – providin
Slide 26: Ethos Labs Partnership
ETHOS LABS PARTNERSHIP: Developer of the world's first biochemical pain index 30,000 ft2 state-of-the-art laboratory For personal use only Implement US “go to market” strategy utilizing Ethos sales force and pain specialists to distribute $12M+ recent expansion investments PainChek across US Aged Ca
Slide 27: PainChek Infant Progress
PAINCHEK INFANT PROGRESS THREE STEP STRATEGY TARGETING MARKET OF 400M PRE-VERBAL CHILDREN Direct to Consumer Marketing • Market testing in progress with parents For personal use only prior to direct-to-consumer (DTC) market entry • Develop channel partners for DTC market entry Enrolling additional H
Slide 28: PainChek Upcoming Catalysts
PAINCHEK UPCOMING CATALYSTS For personal use only Continued acceleration of sales and Complete FDA studies to lodge ARR growth within RAC sector in for US FDA De Novo clearance ANZ, UK, Canada and new EU in Q4 2023 opportunities Enter global hospital market Leverage existing US partnerships sector w
Slide 29: Corporate Summary
CORPORATE SUMMARY For personal use only Top shareholders % Financial information Peters Investments Proprietary Ltd 9.14% Share price (25 July 2023) A$0.028 Board & key staff 4.3% Shares on issue 1,298.0m Founders 5.8% Market capitalisation A$36.3m Cash (30 June 2023) A$2.5m Unlisted options/perform
Slide 30: The Team
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Head of Operations CFO Director, MBA, BSc Officer PhD, MPS Philip is a highly accomplished Jeff is a professor in the Andy is a Psychologist, Iain has over 20 years finance & glob
Slide 31: The Board
THE BOARD For personal use only John Murray Philip Daffas Ross Harricks Adam Davey Cynthia Payne Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Philip is a highly Senior global medical Corporate finance 30 years executive Venture Capit
Slide 32: Quarterly Update July 2023
For personal use only Quarterly Update July 2023 PHILIP DAFFAS, CEO & MD PAINCHEK LTD | ASX:PCK 30 |